What is ARA-290 (cibinetide)?

ARA-290, also called cibinetide, is an 11-amino-acid peptide derived from a region of the erythropoietin (EPO) molecule. Unlike EPO, it does not raise red blood cells. Instead it selectively activates the innate repair receptor to reduce inflammation and support tissue and nerve repair. It is investigational and not FDA-approved.

Does ARA-290 raise red blood cells or blood pressure like EPO?

No. ARA-290 was specifically designed to keep EPO's tissue-protective, anti-inflammatory activity while removing its blood-cell-stimulating (hematopoietic) effect. It targets a different receptor complex than the one EPO uses to make red blood cells, which is the central point of the molecule.

What is ARA-290 studied for?

The most-developed research is in small-fiber neuropathy, including sarcoidosis-associated neuropathy, and neuropathic pain, where Phase 2 trials reported improvements in nerve-fiber measures and pain. It is also studied for broader tissue protection and anti-inflammatory applications. All uses are investigational.

Is ARA-290 FDA-approved?

No. ARA-290 (cibinetide) is an investigational research compound. It has received orphan-drug designation for certain indications during development but is not FDA-approved for any use. Any use should be under physician supervision.

ARA-290 (Cibinetide) — Research Profile

Name: ARA-290 (Cibinetide) — Research Profile
Creator: Dr. Scott DelBoccio, DMD

The Peptide Evidence Index
See how all 34 peptides rank by the strength of real human evidence — one honest scorecard.

View the Index →

Why This Page Exists

The repair half of EPO, without the risk half

Erythropoietin is famous for two unrelated jobs: it tells bone marrow to make red blood cells, and — through a completely different receptor — it protects and repairs injured tissue. The problem is you can't use EPO for the second job without triggering the first, which thickens the blood and raises clot risk. ARA-290 is the elegant solution: a small piece of the EPO molecule that keeps only the repair signal. That single design choice is what makes it interesting for nerve and tissue conditions where nothing else fits.

In one sentenceARA-290 activates the "innate repair receptor" to reduce neuro-inflammation and support small-nerve-fiber repair, with no red-blood-cell or blood-pressure effect — its strongest research is in small-fiber neuropathy and neuropathic pain.

Regulatory Status

Legal & regulatory context

United States — FDA

Investigational · Not Approved

ARA-290 (cibinetide) is an investigational drug developed through clinical trials. It has held orphan-drug designation for certain rare indications during development but is not FDA-approved for any use.

Research Compound

Peptide, Research-Grade

Outside trials, ARA-290 reaches users as a research-grade peptide for subcutaneous use. Sourcing is unregulated; quality and purity vary and a certificate of analysis is essential.

WADA

Verify Independently

As an EPO-derived peptide, ARA-290 sits near a heavily scrutinized class for athletes even though it is non-hematopoietic. Competitive athletes should verify current WADA status before use.

Not Controlled

Not DEA-Scheduled

Not a scheduled substance, but that does not make research-chemical sourcing safe or clinical "cure" claims legal.

Mechanism of Action

How ARA-290 works

It targets the innate repair receptor — not the EPO blood receptor

Tissue protection by EPO runs through a distinct receptor complex (a heteromer of the EPO receptor with the beta-common receptor, CD131) — the "innate repair receptor." ARA-290 binds this complex selectively, so it recruits repair signaling without touching the classic receptor that drives red-blood-cell production.

ARA-290 → innate repair receptor (EPOR/CD131) → ↓ inflammation · ↑ tissue & nerve repair · no hematopoiesis

It resolves inflammation rather than blocking it

Rather than broadly suppressing the immune system, ARA-290 promotes the resolution phase of inflammation — shifting damaged tissue out of a chronic inflammatory state and toward repair. This is why its research clusters around conditions of stalled, low-grade tissue and nerve inflammation.

It supports small-nerve-fiber regeneration

In neuropathy research, the signal of interest is regrowth and function of the small sensory nerve fibers in the skin (measured by corneal nerve-fiber density and skin biopsy), alongside pain reduction — pointing to genuine repair, not just symptom masking.

Primary Use Cases

What ARA-290 is studied for

Small-fiber neuropathy — including sarcoidosis-associated Phase 2
The most-developed research. Trials in sarcoidosis-related small-fiber neuropathy reported improvements in nerve-fiber measures and patient-reported pain and function. This is ARA-290's flagship application.
Neuropathic & chronic pain Clinical
Studied for diabetic and other neuropathic pain, where the tissue-repair and inflammation-resolving mechanism targets the source rather than dulling signals.
Tissue protection & recovery Preclinical
Broader anti-inflammatory, tissue-protective effects in models of metabolic and inflammatory injury — the basis for its interest in the recovery space.
Complex chronic inflammatory conditions Emerging
Discussed for conditions with a neuro-inflammatory component, though clinical validation outside neuropathy is limited.

Who ARA-290 is NOT forIt is not a muscle-building, performance, or general-optimization compound. It's a targeted repair signal for nerve and inflammatory conditions — the evidence and rationale sit there, not in the gym.

Evidence Summary

What the research shows

Basis	Type	Key finding
Sarcoidosis small-fiber neuropathy trials	Phase 2 RCT	Improvements in neuropathic pain, small-nerve-fiber measures, and patient-reported function vs. placebo over the treatment window.
Neuropathic pain studies	Clinical	Reductions in pain scores with a favorable tolerability profile; no hematologic effect observed.
Innate repair receptor mechanism work	Preclinical	Established that tissue protection and hematopoiesis run through separate receptors — the design basis for a non-erythropoietic EPO derivative.
Metabolic / inflammatory injury models	Animal	Anti-inflammatory and tissue-protective effects across multiple organ-injury models.

Relative evidence strength by application

Small-fiber neuropathy

Moderate · Phase 2

Neuropathic pain

Early clinical

Tissue protection

Preclinical

General recovery

Anecdotal

Honest evidence noteARA-290's human data is real but early — Phase 2, in specific neuropathy populations. It is not proven for general recovery or optimization. The mechanism is elegant; the clinical record is still being written.

Protocols & Timeline

Dosing consensus

The ranges below reflect the trial and community record for the subcutaneous research peptide. This is educational reference, not prescribing guidance — ARA-290 is investigational and warrants physician oversight.

Subcutaneous — standard≈ 2–4 mg once daily

Daily subcutaneous administration is the studied route. Trials used a fixed daily dose over a defined treatment window rather than open-ended use.

Cycle lengthMulti-week courses, reassessed

Neuropathy protocols run in courses of weeks, with response measured against nerve-fiber and pain endpoints, then reassessed — not taken indefinitely without evaluation.

What the timeline typically looks like

Weeks 1–2: earliest changes in pain and sensory symptoms in responders.
Weeks 4–8: the meaningful window where pain and function shifts are assessed.
Beyond 8 weeks: nerve-fiber regeneration is slow by nature; durability is evaluated over longer courses under supervision.

Red Flags & Cautions

Where ARA-290 needs care

Investigational status. Human data is early-phase; long-term safety is not characterized.
Source quality. Research-chemical sourcing is unregulated — a third-party certificate of analysis is non-negotiable, and mislabeled or impure product is the most common cause of no effect.
Active malignancy. Any tissue-growth-adjacent signaling warrants physician evaluation and caution in cancer contexts.
Pregnancy / breastfeeding. No safety data — avoid.
Not a substitute for neuropathy diagnosis. Nerve symptoms need a real workup; ARA-290 is not a reason to skip identifying the underlying cause.

Common Questions

ARA-290 questions answered

What exactly is ARA-290?

An 11-amino-acid peptide derived from the "helix B" region of erythropoietin (EPO), also called cibinetide. It keeps EPO's tissue-repair and anti-inflammatory activity while dropping the red-blood-cell-stimulating effect, by acting on the innate repair receptor rather than the classic EPO receptor.

Will it thicken my blood like EPO?

No — that's the whole point of the molecule. It's non-hematopoietic: it doesn't raise red blood cells or hematocrit, because it targets a different receptor complex than the one EPO uses to make blood cells.

What's the strongest evidence for it?

Phase 2 trials in small-fiber neuropathy, including sarcoidosis-associated neuropathy, showing improvements in nerve-fiber measures and neuropathic pain. Everything beyond that — general recovery, broad anti-inflammatory use — is earlier-stage or anecdotal.

Is it approved or legal?

It's investigational, not FDA-approved, and not a controlled substance. It has held orphan-drug designation in development. Any use should be under physician supervision, and vendors claiming it "cures" neuropathy are overstating an investigational compound.

Related Research

Tissue repair & recovery hub

About the Author

Dr. Scott DelBoccio, DMD

Founding Author · PeptideReport.ai

Dr. DelBoccio is a clinician with thirty years of practice and a focus on peptide pharmacology and regenerative medicine. PeptideReport.ai is the clinician-authored, education-only reference the peptide space lacked — every profile is an independent synthesis of the primary literature, evidence-graded and corrected in the open. No products are sold on this site.

Full Disclaimer

ARA-290 (cibinetide) is not approved by the U.S. Food and Drug Administration for any indication and is an investigational research compound. Information on this page is for educational and scientific purposes only and does not constitute medical advice, diagnosis, or treatment. Protocols described are drawn from published trials and community practice; they are not prescribing guidance. Neuropathy and chronic pain require diagnosis and management by a qualified physician. PeptideReport.ai does not manufacture, sell, or endorse any peptide preparation. Content addresses adults 21 and older. Evidence and regulatory classifications continue to evolve.